Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 dose-finding phase IIb study in palmoplantar pustulosis
NL-OMON48187Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of spesolimab in Palmoplantar Pustular Psoriasis (PPPP) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percent change in PPP ASI from baseline at Week 16. Started Oct 2019; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on NL-OMON48187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48187.